From regional expansion to variety expansion, drug volume procurement is gradually normalized

[industry trends of pharmaceutical network] on January 21, the results of the second round of national drug centralized procurement were officially published In this round of centralized purchase, 32 varieties were purchased successfully, 100 products were selected, and 77 enterprises were proposed to be selected Specifically, the average price reduction of the centralized purchase reached 53%, and the high price reduction reached 93% In particular, the price reduction of the regular drugs for chronic diseases such as acarbose and glimepiride was significant, which was conducive to further reducing the burden of patients According to the arrangement, patients from all over the country can use this batch of selected drugs in April The centralized purchase policy of drugs organized by the state has a great influence on patients and enterprises For patients, it is beneficial for pharmaceutical enterprises to declare their own quotation according to the purchase volume and realize the link between quantity and price, so as to squeeze out the virtual high space of drug price and benefit patients; for pharmaceutical enterprises, although many pharmaceutical enterprises are facing the pressure of fierce market competition and cost control However, the centralized procurement with a volume of medical insurance funds in advance or medical insurance funds directly settle accounts with enterprises, further reducing the cost of funds for pharmaceutical enterprises A survey shows that the 30 day settlement rate of the products selected in the "4 + 7" pilot has reached more than 90%, to avoid the problem of medical institutions defaulting on the payment of enterprises In December 2018, the "4 + 7" pilot results of centralized volume bidding procurement of drugs organized by the state were generated, and 25 drugs were selected, with an average decrease of 52% compared with the low purchase price of the same kind of drugs in the pilot cities in 2017 Since March 2019, the "4 + 7" pilot areas have successively carried out the selection results of volume procurement In addition, from December 2019, other provinces across the country began to implement the results of the expansion of centralized procurement, and patients across the country enjoy the price reduction policy The author noted that under the "4 + 7" pilot and the expansion policy, most of the drugs were used for chronic diseases and major diseases such as hypertension, psychosis, viral hepatitis and malignant tumor The patients who took these drugs had a heavy burden because they needed to buy drugs for a long time With the promotion of the pilot and expansion policies, the procurement implementation of the pilot cities exceeded expectations and completed the agreed procurement volume in advance By the end of December 2019, the average procurement implementation progress of 25 pilot areas of "4 + 7" selected drugs was 183%, and the selected drugs accounted for 78% of the same generic drugs The burden of patients was greatly reduced, and the level of clinical medication quality was greatly improved On December 29, 2019, the second batch of national drug centralized procurement was officially launched 33 varieties were selected for this batch of Drugs centralized procurement, covering the treatment fields of diabetes, hypertension, anti-tumor and rare diseases The scope of varieties expanded further, involving more than 100 pharmaceutical manufacturers In addition, according to the data, the purchase volume base is 12.4 billion pieces (bags / piece), and the agreed purchase volume of each variety is 50-80% of the purchase volume base According to this calculation, the purchase scale of 33 varieties of drugs in the second round will reach 9 billion yuan Among them, the procurement scale of acarbose and tegio exceeded 1 billion yuan The purchase amount of acarbose was 2.928 billion yuan, and that of tegio was 1.045 billion yuan Industry insiders said that at present, the policy of volume purchase has been normalized, with the expansion of regions first, and now to the expansion of varieties In the future, as more generic drug consistency evaluations are completed, the dosage forms will gradually expand from oral to injection In this context, relevant pharmaceutical manufacturers need to seize the opportunity to seize the market.